Trials / Completed
CompletedNCT02354235
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin in Patients With Inadequate Glycemic Control on Teneligliptin)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 138 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 24 weeks in Japanese patients with Type 2 diabetes mellitus who are receiving treatment with Teneligliptin and have inadequate glycemic control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teneligliptin | |
| DRUG | Canagliflozin | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2016-01-01
- Completion
- 2016-01-01
- First posted
- 2015-02-03
- Last updated
- 2026-01-07
- Results posted
- 2018-08-16
Locations
3 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02354235. Inclusion in this directory is not an endorsement.